PJHRD
Philippine Journal of Health Research and Development
University of the Philippines Manila - The Health Sciences Center
Information, Publication and public affairs Office (IPPAO)
8/F Philippine General Hospital Complex, Taft Avenue, Manila 1000 Philippines

Online ISSN: 2783-042X
April-June
VOL. 29 NO. 2 2025
PAGE 35-41

RESEARCH ARTICLE

Strengths, Weaknesses, Opportunities, and Threats (SWOT) analysis of the establishment of the University of the Philippines Pharmaceutical Science Service Laboratory (UP PSSL)

John Nicolas B. Mejia* and Bienvenido S. Balotro
College of Pharmacy, University of the Philippines Manila, Manila, Philippines

ABSTRACT

The Strength, Weaknesses, Opportunities, and Threats (SWOT) Analysis of the Establishment of the University of the Philippines Pharmaceutical Science Service Laboratory (UP PSSL) delves into the critical role of pharmaceutical research and service laboratories in advancing drug development, ensuring patient safety, and fostering healthcare innovation. Through a meticulous examination encompassing a literature review, SWOT analysis and Key Informant Interviews (KII), this study evaluates the internal strengths and weaknesses of proposed services such as Product Development, Pharmacokinetic Studies, Therapeutic Drug Monitoring, and Biowaiver Studies. By aligning these services with market demands and regulatory standards, the UP PSSL aims to become a pivotal player in the pharmaceutical research landscape. The validation process through KII ensures that strategic decisions are informed by stakeholder perspectives, enhancing the laboratory's operational efficiency and contribution to the industry.

Introduction

In the pharmaceutical sector, the demand for novel drugs to address unmet medical needs across diverse therapeutic areas is increasing. To introduce new drugs to the market, drug research and development are prioritized. The process involves discovery, which includes target selection, hit identification, lead optimization, and candidate selection, and development, which encompasses chemical synthesis improvement, formulation, toxicity studies, clinical trials, and regulatory approval [1]. These processes are time and cost-intensive, with challenges such as regulatory requirements, environmental concerns, and revenue decline from patent expirations affecting R&D efficiency. Collaboration and innovation among businesses, academia, and government research organizations are essential to deliver high-quality pharmaceutical products [1,2].

The country's pharmaceutical industry is expected to grow to Php 216 billion by 2024, highlighting the Philippines as an increasingly attractive market for pharmaceutical firms [3]. This local projection aligns with the global trend in the pharmaceutical sector, where the preclinical drug discovery market is a critical component for sustainability. With research and development spending anticipated to reach $200 billion (Php 11 trillion) globally by 2024, this substantial investment underscores the necessity of continued innovation and development within the industry [4]. As the global market expands, the Philippines stands to benefit significantly from the projected growth both locally and internationally. The burgeoning local pharmaceutical market, combined with the urgent need for advanced research and development in preclinical drug discovery, positions the Philippines not just as a participant but as a potential leader in the regional drug industry.

The drug development process is lengthy, expensive, and complex, taking 12 to 15 years from target identification to market introduction per drug [4]. Contract Research Organizations (CROs) play a vital role in drug research across the lifecycle, offering services from conceptualization to Phase 4 clinical trials. Pharmaceutical companies benefit from using CROs to reduce overhead costs and explore multiple drug candidates simultaneously. CROs are also utilized by research organizations, universities, and government agencies. Contract Manufacturing Organizations (CMOs) and CROs provide end-to-end solutions and formulation development, aiding in cost reduction and infrastructure utilization for drug makers worldwide [5].

The surge in clinical trials during the COVID-19 pandemic underscores the need for effective medicines management and adherence to regulatory standards like Good Clinical Practice (GCP), Good Laboratory Practice (GLP), and Good Manufacturing Practice (GMP) [6-8]. In this evolving landscape, the UP PSSL has the potential to significantly enhance the local clinical trial market by providing state-of-the-art facilities that support foreign clinical research organizations interested in conducting trials in the Philippines. Additionally, UP PSSL can aid local drug discovery initiatives, such as the Department of Science and Technology (DOST) Tuklas Lunas Program, by facilitating preclinical studies and the development of clinical trial materials. This strategic positioning would not only attract international research but also strengthen the Philippines' capacity for local testing and innovation in drug development.

The availability of pharmaceutical expertise, facilities, and services is crucial for maintaining the quality and credibility of clinical trials. The establishment of the UP PSSL by the UP College of Pharmacy and the Institute of Pharmaceutical Sciences of the National Institutes of Health (NIH) aims to support the NIH National Clinical Training Research Center by providing essential pharmaceutical services for all phases of clinical trials, including pharmacokinetic drug profiling, bioavailability testing, quality control, and therapeutic drug monitoring.

The SWOT Analysis of the Establishment of the UP PSSL is a comprehensive analysis aimed at evaluating the viability of setting up a cutting-edge pharmaceutical research and service laboratory at the UP Manila. This study focuses on providing services in Product Development and Compounding of Clinical Trial Materials, Pharmacokinetic Studies and Bioanalytical Testing, Therapeutic Drug Monitoring and Drug Utilization Studies, and Biowaiver Studies. Each thematic area plays a crucial role in advancing pharmaceutical research and development, ensuring the safety and efficacy of drugs, and contributing to the overall improvement of healthcare practices.

The UP PSSL will house a state-of-the-art Compounding and Product Development Laboratory dedicated to the formulation and compounding of pharmaceuticals and clinical research materials. This facility will play a key role in supporting local and international researches focused in developing new drugs and improving existing formulations for investigational products. Through pre-formulation and formulation studies, validation, stability studies,

Corresponding author's email address:
jbmejia2@up.edu.ph
Keywords: pharmaceutical science, service laboratory, SWOT Analysis, market demands, clinical trial materials, academic, pharmaceutical industry
Date submitted: November 13, 2024
Date accepted: March 21, 2025

and compounding of clinical trial research materials, the laboratory will support the entire drug development process from pre-clinical studies to clinical trials. Another essential component of the UP PSSL is the Bioequivalence Laboratory, which will specialize in conducting pharmacokinetic studies and bioanalytical testing. This laboratory will play a critical role in assessing the bioequivalence of generic drugs compared to their branded counterparts, ensuring their safety and efficacy.

Furthermore, the UP PSSL will provide services in therapeutic drug monitoring, a practice that involves measuring drug levels in patients' blood to ensure optimal dosing and minimize adverse effects. Additionally, the laboratory will conduct drug utilization studies to evaluate the patterns of drug use in specific populations, helping healthcare providers make informed decisions about prescribing practices and patient care. Lastly, Biowaiver studies are crucial in determining whether a generic drug can be considered bioequivalent to its reference product without the need for additional clinical trials. The UP PSSL will focus on developing biowaiver monographs and providing bioanalytical services to support the approval of generic drugs.

The establishment of the UP PSSL, with a focus on Product Development and Compounding of Clinical Trial Materials, Pharmacokinetic Studies and Bioanalytical Testing, Therapeutic Drug Monitoring and Drug Utilization Studies, and Biowaiver Studies represents a significant step towards enhancing pharmaceutical research and service capabilities in the Philippines. By offering a wide range of high-quality services and expertise, the laboratory is poised to become a key player in advancing drug development, ensuring patient safety, and promoting healthcare innovation.

Methodology

The study applied a comprehensive literature review following the PRISMA criteria to establish the SWOT analysis of the proposed services. The review was performed using the Science Direct and Google Scholar databases, employing Boolean operators and targeted keywords such as "Pharmaceutical Service," "Product Development," "Clinical Trials," "Pharmacokinetic Studies," "Bioanalytical Testing," "Therapeutic Drug Monitoring," "Drug Utilization Studies," and "Biowaiver Studies" wherein 15 articles passed the criteria and therefore included in the analysis. This comprehensive review served as the basis for the subsequent SWOT analysis, which retrospectively evaluated the internal strengths and weaknesses of the proposed services, as well as external opportunities and threats that could impact the feasibility of establishing the UP PSSL.

Following the completion of the SWOT analysis, the study progressed to the validation phase through Key Informant Interviews (KII) with 10 informants which comprised of industry experts, academic researchers, regulatory experts and potential clients. These interviews aimed to validate and enhance the insights derived from the literature review and SWOT analysis, providing a retrospective validation of the initial findings.

Limitations

The method KII employed in this research does have limitations, primarily due to the intentional decision to withhold specific participant profiles to protect their confidentiality. While this respect for privacy encourages candid contributions, it may also limit the depth of analysis regarding individual perspectives and experiences within the pharmaceutical industry. Furthermore, although the KIIs were facilitated during a reputable Industry Consultation Workshop organized by the DTI and ADB, the reliance on a select group of industry experts may restrict the diversity of viewpoints represented, potentially leading to a narrower understanding of the broader industry dynamics. Nevertheless, the commitment to ethical research practices ultimately strengthens the integrity of the findings by promoting an environment of trust among participants.

Ethical Clearance

The research study has received exemption from ethical review by the University of the Philippines Manila Research Ethics Board (UPMREB) (UPMREB 2024-0354-EX). This exemption indicates that the study protocol, focusing on the SWOT Analysis of establishing the UP PSSL, has been deemed to pose minimal or no risk to participants' rights, safety, or well-being.

Results

The UP PSSL is poised to address critical gaps in drug research and development through its proposed specialized services (Table 1). Recognizing the increasing demand for innovative pharmaceutical solutions, UP PSSL aims to provide comprehensive product development and compounding capabilities, including the optimization and validation of formulations, small-scale manufacturing of clinical trial materials, and essential stability studies that ensure the safety and efficacy of drug products. Additionally, the Therapeutic Drug Monitoring Unit will enhance patient care by conducting drug utilization reviews and therapeutic drug monitoring studies that facilitate personalized medicine through optimized dosing strategies. The In Vitro Pharmacokinetic Laboratory will provide pharmacokinetic profiling and bioanalytical testing to assess drug behavior in vivo, informing better therapeutic outcomes. Lastly, the Biowaiver Laboratory will focus on conducting permeability and solubility studies, as well as developing biowaiver monographs that can expedite regulatory processes for drug approval.

Product Development and Compounding of Clinical Trial Materials

The Philippines' growing pharmaceutical research and development sector is driving demand for high-quality clinical trial materials, contributing to the country's expanding pharmaceutical market [9,10], which is projected to reach US$1,983.00 million in revenue by 2025. With Oncology Drugs leading at US$298.20 million, the market is expected to grow at a CAGR of 4.08% (2025-2029), reaching US$2,327.00 million by 2029. Additionally, the increasing demand for affordable generic drugs further fuels market expansion, positioning the country as a key player in the industry, though it still trails behind global leaders like the United States, which is projected to generate US$660.00 billion in 2025 [11].

By offering services for product development and compounding, the UP PSSL can cater to local pharmaceutical manufacturers, academic researchers, and government agencies, enhancing its market competitiveness and revenue potential. Additionally, the laboratory's strategic location at the University of the Philippines Manila provides access to a pool of highly qualified personnel and academic resources, further strengthening its capabilities in this service area.

On the flip side, weaknesses in product development and compounding services may include initial investment costs for acquiring state-of-the-art equipment and ensuring compliance with regulatory standards [12-14]. However, these challenges can be mitigated through strategic partnerships with industry stakeholders and leveraging funding opportunities available through academic collaborations and government initiatives. The UP PSSL can establish strategic partnerships with local pharmaceutical companies, leveraging government grants from the DOST to support product development,

Table 1. Proposed Services of the University of the Philippines Pharmaceutical Science Service Laboratory (UP PSSL)

Laboratory	Proposed Services
Product Development and Compounding Laboratory	1. Product development, optimization and validation 2. Small scale manufacturing of clinical rial materials 3. Stability studies of drug product
Therapeutic Drug Monitoring Unit	1. Drug utilization review studies 2. Therapeutic drug monitoring studies
In Vitro Pharmacokinetic Laboratory	1. Pharmacokinetic profiling and bioanalytical testing studies in vitro
Biowaiver Laboratory	1. Permeability studies of drug candidates 2. Solubility studies of drug candidates 3. Biowaiver studies and biowaiver monograph development

optimization, and validation of new formulations. For example, by collaborating with a local pharmaceutical firm or the Tuklas Lunas Program pipelime of the DOST, UP PSSL can facilitate small-scale manufacturing of clinical trial materials while also conducting stability studies on these products, ensuring that they meet regulatory standards for safety and efficacy before advancing to market. Opportunities in this service area lie in the potential for innovation and differentiation in the local pharmaceutical market, particularly in the Philippines, where the increasing demand for quality medicines presents a ripe environment for novel solutions. For instance, by focusing on the development of locally sourced herbal product or generic equivalent, UP PSSL can promote innovation that addresses both the cultural preferences of Filipino consumers and the growing trend towards natural and traditional remedies. Additionally, engaging in biopharmaceutical research to create affordable biosimilars can also establish differentiation in a market currently dominated by imported products. The success of similar initiatives in the African context serves as a compelling justification for this approach. For example, in countries like South Africa, the establishment of local pharmaceutical manufacturers that leverage indigenous knowledge and raw materials has led to significant advancements in drug availability and affordability [12]. Such evidence supports the argument that the Philippines can benefit from a strategic emphasis on innovation within its pharmaceutical landscape, fostering a sustainable and self-sufficient industry that can compete globally.

By offering specialized services for clinical trial materials development, the UP PSSL can position itself as a leader in pharmaceutical research and service provision, attracting clients both locally and internationally. What sets us apart from our competitors is our strategic positioning as the pioneer in contract development and manufacturing organizations (CDMOs) in the Philippines that is university based. Our specialized services include custom formulation development, regulatory compliance support, and efficient production techniques that prioritize quality and sustainability. Additionally, our strategic collaborations with local universities and research institutions will bolster our position as an industry leader in pharmaceutical research, enabling us to drive innovation and improve patient outcomes across the region.This can lead to long-term sustainability and growth for the laboratory, contributing to the advancement of the Philippine pharmaceutical industry.

In terms of threats, competition from existing CROs and regulatory complexities in product development and compounding may pose challenges to the UP PSSL [12-14]. By conducting a thorough SWOT analysis and proactively addressing these threats, the laboratory can formulate specific strategies to differentiate itself, enhance its service offerings, and ensure compliance with regulatory requirements. To effectively address the threats posed by competition from established CROs and the regulatory complexities inherent in product development and compounding, UP PSSL, as the first university-based CDMO in the Philippines, must leverage its unique position and capabilities. By conducting a thorough SWOT analysis, we identified our distinct advantages, such as access to cutting-edge research, academic expertise, and collaboration opportunities with faculty and students. This will allow us to enhance our service offerings with innovative and customized solutions that address specific client needs, setting us apart from traditional CROs. Additionally, we can establish a proactive compliance strategy by investing in specialized training for our staff and developing streamlined processes to navigate regulatory requirements effectively. Collaborating with local regulatory bodies will also foster transparency and trust. By positioning UP PSSL as not only a manufacturing hub but also a leader in regulatory knowledge and innovation, we can attract clients seeking tailored solutions that prioritize both quality and compliance, ultimately solidifying our competitive edge in the market. Moreover, the increasing emphasis on research and innovation in the Philippines presents an opportunity for the UP PSSL to collaborate with local research institutions and industry partners, fostering a collaborative ecosystem that supports the development of high-quality clinical trial materials.

Pharmacokinetic Studies and Bioanalytical Testing

According to Ingle *et al.*, 2022 pharmacokinetic studies and bioanalytical testing have potential impact on the local pharmaceutical landscape [15]. Pharmacokinetic Studies and Bioanalytical Testing are critical components of the SWOT analysis for the UP PSSL within the Philippine context. Conducting a SWOT analysis specific to these services provides valuable insights into their feasibility and potential impact on the local pharmaceutical landscape. The significance of is pronounced despite the absence of direct references to the Philippines in existing literature. This laboratory can harness these methodologies to meet the rising demand for local pharmaceuticals, ensuring they are attuned to the specific responses of the Filipino population. By conducting these studies, UP PSSL can facilitate regulatory compliance, enhance the quality of local drug development, and contribute to improved health outcomes in the Philippines, thus underscoring the vital role of these services in strengthening the national pharmaceutical landscape.

In terms of strengths, the Philippines has a growing pharmaceutical industry that requires robust pharmacokinetic studies and bioanalytical testing to ensure the safety and efficacy of pharmaceutical products [16,17]. By offering these services, the UP PSSL can cater to the needs of pharmaceutical manufacturers, researchers, and regulatory bodies, positioning itself as a reliable and high-quality service provider in the market. By offering these targeted services, UP PSSL can cater to the specific needs of pharmaceutical manufacturers, researchers, and regulatory bodies. This strategic positioning not only addresses immediate market needs but also ensures the laboratory becomes known as a reliable and high-quality service provider in the market. Ultimately, this approach enables UP PSSL to solidify its role as an essential player in the public health sphere, ensuring that its offerings resonate with the current requirements of the Philippine pharmaceutical sector. Additionally, the laboratory's academic expertise from the UP College of Pharmacy and the NIH - Institute of Pharmaceutical Sciences provides a strong research foundation, enhancing its credibility and capabilities in conducting pharmacokinetic studies and bioanalytical testing.

However, weaknesses in this service area may include the need for specialized equipment and expertise, as well as the potential for high operational costs associated with conducting pharmacokinetic studies and bioanalytical testing [13,14]. While the demand for pharmacokinetic studies is critical in shaping the pharmaceutical landscape, current literature and interviews do not provide specific figures indicating the exact demand levels within the Philippines. This lack of quantified data presents a challenge for public institutions like the UP PSSL in determining how to allocate resources effectively. However, this gap can also be viewed as an opportunity; by strategically evaluating and identifying key areas of need within the local market—such as focusing on pharmacokinetic studies relevant to common diseases or prevalent medications within the country—UP PSSL can tailor its services to better align with market demand. To address these challenges, the UP PSSL can explore partnerships with industry stakeholders, academic institutions, and government agencies to access resources, funding, and technical support. Moreover, opportunities in pharmacokinetic studies and bioanalytical testing lie in the increasing demand for these services in the local pharmaceutical market [9,10]. With the Philippines emerging as a hub for pharmaceutical research and development, there is a growing need for reliable and efficient pharmacokinetic and bioanalytical services, presenting a significant opportunity for the UP PSSL to establish itself as a key player in this niche area.

In terms of threats, competition from established CROs and regulatory hurdles in conducting pharmacokinetic studies and bioanalytical testing may pose challenges to the UP PSSL just like the issues in Africa [17]. In the Philippines, the UP PSSL faces significant threats due to competition from established contract research organizations (CROs) and the regulatory hurdles associated with conducting pharmacokinetic studies and bioanalytical testing. CROs, many of which are already well-entrenched in the South-East Asian market, typically offer competitive pricing and faster turnaround times due to their larger workforce, established protocols, and existing relationships with international pharmaceutical companies. This drives local institutions like UP PSSL to compete on a challenging playing field where they may struggle to match the cost-efficiency and rapid service delivery of these organizations. Additionally, the Philippine regulatory framework, while designed to ensure safety and efficacy, can often be cumbersome and lengthy, potentially prolonging the approval process for studies. Delays in obtaining necessary permissions can deter both local and foreign clients who may seek quicker solutions from CROs, further exacerbating the competitive disadvantage faced by UP PSSL. Additionaly, by leveraging its academic expertise, strategic partnerships, and government support, the laboratory can differentiate itself by offering tailored services, ensuring compliance with regulatory standards, and providing innovative solutions to meet the evolving needs of the pharmaceutical industry. By leveraging its academic expertise in pharmacokinetics, bioanalytical testing, and drug formulation, UP PSSL can differentiate itself through several strategic approaches. The laboratory collaborates with industry partners, including the University of the Philippines System and various institutions like Department of Science and Technology, to

enhance research capabilities and resource sharing. Tailored services may include customized pharmacokinetic modeling, specialized bioanalytical testing for local drugs, and rapid turnaround times for early-stage studies, all provided at competitive pricing to ensure cost-effectiveness. Furthermore, UP PSSL aims to innovate by integrating cutting-edge technologies such as high-throughput screening and advanced data analytics into its research processes. Furthermore, the emphasis on research and innovation in the Philippines creates a conducive environment for the UP PSSL to collaborate with local researchers, industry partners, and regulatory bodies, fostering a culture of excellence and continuous improvement in pharmacokinetic studies and bioanalytical testing.

Therapeutic Drug Monitoring and Drug Utilization Studies

Therapeutic drug monitoring and drug utilization studies in optimizing patient care and treatment outcomes [18,19]. These services are highly applicable to the Philippine context. Conducting a SWOT analysis specific to these services offers significant insights into their feasibility and potential impact on the local pharmaceutical landscape.

The Philippines' healthcare system is increasingly recognizing the importance of Therapeutic Drug Monitoring (TDM) and drug utilization studies for optimizing patient care and treatment outcomes. Given the rising prevalence of diseases requiring precise medication regimens, TDM ensures that patients receive appropriate therapeutic doses, thus improving health outcomes and reducing hospital readmissions [20]. Additionally, drug utilization studies provide critical insights into prescribing patterns and medication compliance, which are essential for informed policymaking and tackling public health issues, such as antibiotic resistance. By identifying medication use trends, UP PSSL can empower healthcare providers with the knowledge needed for evidence-based practices that enhance patient safety and treatment efficacy. By offering these services, UP PSSL can position itself as a valuable partner to healthcare providers, hospitals, and pharmaceutical companies in promoting rational drug use and personalized medicine [21]. Its academic expertise and state-of-the-art facilities further enhance its credibility and competitiveness in the market, contributing significantly to improving the national healthcare system.

In the context of the UP PSSL, recognizing and addressing the inherent weaknesses within its TDM and drug utilization study services is crucial for maximizing its potential impact on national healthcare. Key weaknesses include the need for specialized equipment, trained expertise, robust data analysis capabilities, and the challenges associated with data interpretation and reporting [13,14,18]. To confront these challenges, UP PSSL can undertake several strategic measures. For example, investing in comprehensive training programs will equip staff with the necessary skills to conduct sophisticated analyses and interpret complex data accurately. Collaborating with local healthcare institutions can enhance data sharing and foster a network of mutual support, thereby improving the quality and reliability of data collected in TDM and drug utilization studies. Implementing stringent quality assurance measures can further ensure the accuracy of results, building credibility among stakeholders and fostering trust in UP PSSL's findings.

Additionally, the growing demand for evidence-based medicine and personalized treatment approaches presents significant opportunities for UP PSSL. In the Philippines, a shift toward precision medicine, which tailors treatment based on individual patient profiles, is becoming increasingly prominent [18,19]. For instance, pharmacogenomic testing allows for tailored medication regimens that consider genetic makeup, resulting in better therapeutic outcomes and reduced adverse drug reactions. This emerging trend amplifies the necessity for TDM and drug utilization studies, providing UP PSSL with the opportunity to lead in this critical area of healthcare. Moreover, by establishing itself as a pioneer in these fields, UP PSSL could leverage partnerships with pharmaceutical companies and research institutions, securing funding and resources for further innovations. For example, collaborative studies could advance knowledge on medication efficacy and safety, pushing the frontiers of pharmacotherapy in the region.

The UP PSSL faces significant threats in the competitive landscape of TDM and drug utilization studies, particularly from well-established clinical laboratories and the complexities of navigating regulatory frameworks in these domains. Nevertheless, UP PSSL can strategically position itself to overcome these challenges by leveraging its strong academic partnerships and industry collaborations, which offer a foundation for innovation and credibility. For instance, by adhering to international quality standards, UP PSSL can differentiate its services, providing comprehensive TDM that includes real-world data analytics and evidence-based insights tailored to the needs of healthcare stakeholders. This approach can enhance its value proposition to healthcare providers and policymakers, who increasingly prioritize rational drug use and optimized treatment regimens to improve patient safety. Simultaneously, the changing healthcare landscape in the Philippines, characterized by a growing emphasis on personalized medicine and patient-centered care, presents UP PSSL with unique opportunities to engage actively with pharmaceutical companies in research and development initiatives aimed at addressing the local healthcare landscape's multifaceted challenges.

Biowaiver Studies

Biowaiver Studies are integral to the SWOT analysis for the UP PSSL within the Philippine context. Conducting a SWOT analysis specific to Biowaiver Studies offers valuable insights into their feasibility and potential impact on pharmaceutical research and regulatory processes in the country. In terms of strengths, Biowaiver Studies play a crucial role in streamlining the drug approval process, reducing costs, and promoting access to essential medications [22-24]. By offering specialized services focused on ensuring the quality and safety of generic drug products, the UP PSSL can play a pivotal role in supporting local pharmaceutical manufacturers, regulatory agencies, and healthcare providers. This commitment not only positions UP PSSL as a key player in the advancement of pharmaceutical research and development but also addresses the critical demand for rigorous quality assurance in the generics market, which constitutes a substantial portion of medication dispensed in the Philippines. Recent literature indicates a growing need for reliable TDM and biowaiver studies as healthcare providers increasingly seek to optimize treatment efficacy while minimizing adverse effects, particularly given the rising prevalence of chronic diseases (e.g., diabetes and hypertension) necessitating complex medication regimens [25].

Furthermore, the laboratory's academic expertise, coupled with its state-of-the-art facilities and strict adherence to international regulatory standards, provides a robust framework for conducting Biowaiver Studies—critical for generic drug approval in the competitive global market. For example, leveraging data from successful partnerships with reputable pharmaceutical companies could enhance the laboratory's credibility in the eyes of both regulators and healthcare stakeholders. This positions UP PSSL not just to meet existing market demand, but to anticipate future needs and develop new services that align with emerging trends, such as personalized medicine and pharmacogenomics. Such proactive engagement ensures that UP PSSL avoids oversupply scenarios by tailoring its service offerings to actual market demand rather than speculative interests, ultimately maximizing its potential revenue and sustaining its operations.

While the UP PSSL provides critical services in Biowaiver Studies, it faces inherent weaknesses in the specialization required for bioequivalence testing, the need for sophisticated equipment, and deep knowledge of regulatory compliance. For instance, conducting thorough bioequivalence studies necessitates advanced analytical technologies like high-performance liquid chromatography (HPLC) and mass spectrometry, both of which require significant financial investment and technical expertise [13,14,18]. Additionally, navigating the complex regulatory landscape—especially given the stringent requirements for drug approval in the Philippines set forth by the Food and Drug Administration (FDA)—demands not only familiarity with local legislation but also international standards, which can be daunting for smaller institutions.

To address these challenges effectively, the UP PSSL could initiate specialized training programs for its staff, ensuring they are well-versed in both the technical and regulatory dimensions of bioequivalence testing. Collaborating with regulatory authorities such as the FDA could provide valuable insights and aid compliance, while implementation of robust quality assurance measures would ensure accurate and reliable results. For example, engaging in continuous quality improvement workshops could empower staff with the latest best practices in both analytical techniques and regulatory affairs.

The increasing demand for generic drug products, emphasized by healthcare initiatives aimed at improving access to essential medications, presents substantial opportunities for UP PSSL. A report by Martir *et al*. (2020) indicates that the Filipino population is significantly reliant on generic

drugs, especially in the face of rising healthcare costs [26]. This trend aligns with a national priority to enhance access to affordable healthcare, further underpinning the urgency for cost-effective drug development strategies [27]. Consequently, there is a notable market for Biowaiver services that can facilitate the timely introduction of generics, effectively positioning UP PSSL as a leader in supporting the pharmaceutical sector.

However, the laboratory must remain vigilant of threats such as competition from established research institutions and changing regulatory requirements that could lead to market saturation. To differentiate itself, UP PSSL can capitalize on its strong academic partnerships and collaborative projects with industry to offer comprehensive Biowaiver services enriched with innovative research and evidence-based recommendations for pharmaceutical stakeholders and regulatory bodies. For instance, by leading initiatives that promote bioequivalence testing and by actively engaging with local manufacturers in outreach programs, UP PSSL not only reinforces its position in the marketplace but also contributes positively to public health initiatives aimed at ensuring the availability of safe, effective, and affordable medications in the Philippines.

Stakeholders Analysis

The stakeholder analysis for proposing the UP PSSL involves engaging with industry partners and the Department of Trade and Industry (DTI) to assess the potential impact and feasibility of the proposed laboratory. The process aims to identify and understand the interests, concerns, and influence of key stakeholders to ensure the successful establishment and operation of the laboratory.

The successful establishment and operation of the UP PSSL requires a comprehensive understanding of the interests, concerns, and influence of key stakeholders. The KII involved 1o informants including industry partners, regulatory bodies, academic institutions, government agencies, and the broader community.

Table 2 shows that pharmaceutical industry is increasingly focused on several key areas of development to enhance drug accessibility and patient outcomes. In Product Development and Compounding Laboratories, there is a strong interest in innovative formulations that cater to personalized medicine while ensuring quality through adherence to Good Manufacturing Practices (GMP). Therapeutic Drug Monitoring Units aim to optimize individualized therapy by leveraging data analytics to manage complex medication regimens and aligning practices with regulatory guidelines. Meanwhile, In Vitro Pharmacokinetic Laboratories emphasize studies on drug absorption and metabolism, employing predictive modeling to ensure efficient drug development while meeting compliance standards. Lastly, Biowaiver Laboratories facilitate quicker market entry for generics through biowaiver studies that adhere to international regulations, thereby enhancing access to affordable medications. Collectively, these areas highlight a commitment to advancing pharmaceutical development while prioritizing safety and efficacy.

The UP PSSL is fortified by several substantial strengths that underline its potential to become a leader in the pharmaceutical research sector. Its robust academic foundation, derived from its affiliation with the UP College of Pharmacy and the NIH Institute of Pharmaceutical Sciences, provides a wellspring of expertise and cutting-edge knowledge. This academic rigor equips the laboratory to undertake high-quality pharmaceutical research and efficient laboratory operations, which are essential for delivering reliable analytical services. Moreover, the laboratory benefits from secure government funding, ensuring financial stability that enables sustainable operations and investments in advanced technologies. Its strategic location within the UP system facilitates access to a rich talent pool of researchers, students, and potential industry partnerships, fostering an innovative environment where collaboration can thrive. This combination of expertise, funding stability, and access to talent is instrumental in UP PSSL's mission to advance pharmaceutical sciences and contribute meaningfully to the industry.

However, the UP PSSL must confront several weaknesses that may impede its growth and effectiveness. One significant challenge is its limited industry experience, which can hinder its ability to understand and address the specific needs of commercial clients effectively. Without a deep understanding of market dynamics, the laboratory may struggle to tailor its services to meet industry demands, potentially missing out on lucrative contracts or partnerships. Additionally, as a nascent entity, UP PSSL faces the uphill task of establishing brand recognition and credibility in a competitive landscape populated by well-established laboratories. This lack of familiarity can deter prospective clients who may prioritize proven track records over new entrants. It is essential for UP PSSL to strategize how to build its reputation through effective marketing, outreach, and prompt delivery of quality services that underscore its academic strengths while addressing these operational challenges.

Despite the obstacles, UP PSSL stands on the precipice of numerous opportunities that could substantially enhance its market position. Notable among these is the potential to forge partnerships with local pharmaceutical manufacturers, which could streamline the development of analytical services to meet specific industry requirements. By engaging with these stakeholders, UP PSSL can gain valuable insights into emerging market needs, enabling it to adjust its services accordingly and foster a collaborative ecosystem beneficial for all parties involved. Moreover, the laboratory's commitment to embracing technological advancements aligns with the broader pharmaceutical industry's trajectory toward innovation, particularly in areas such as drug development and precision medicine. By investing in state-of-the-art equipment and practices, UP PSSL can enhance its operational capacity and effectiveness, attracting an array of clients eager for sophisticated analytical services. Engaging local traders and manufacturers not only serves to solidify partnerships but also positions the laboratory as an integral participant in the regional pharmaceutical narrative, opening pathways to greater industry influence and recognition.

Table 2. Summary of Industry Interests in Pharmaceutical Development

Domain	Interest
Product Development and Compounding Laboratory	• Focus on innovative formulations and customization to improve patient adherence. • Emphasis on quality assurance and compliance with Good Manufacturing Practices (GMP). • Interest in collaboration with healthcare providers for personalized medicine solutions. • Goals of cost-effectiveness to enhance access to essential medications.
Therapeutic Drug Monitoring Unit	• Aim to optimize personalized therapy through individualized dosing strategies. • Integration of advanced data analytics to manage complex medication regimens. • Commitment to educating healthcare professionals on TDM practices. • Alignment with regulatory guidelines to ensure safe and effective practices.
In Vitro Pharmacokinetic Laboratory	• Focus on conducting studies of drug absorption and metabolism (ADME) for efficient development. • Interest in predictive modeling to correlate in vitro results with in vivo outcomes. • Ensuring compliance with regulatory requirements for drug approval. • Adoption of innovative technologies to enhance data relevance and accuracy.
Biowaiver Laboratory	• Support for facilitating generic drug market entry through biowaiver studies. • Commitment to complying with international regulatory standards. • Aim to enhance patient access to affordable medications in various markets. • Collaboration with academia and industry to refine biowaiver methodologies.

Table 3. Summary of Identified SWOT of UP PSSL based on the literature review , key informant interviews (KII)

Domain	Key points
Strengths	• Strong academic expertise from affiliation with UP College of Pharmacy and NIH - Institute of Pharmaceutical Sciences. • Solid foundation for high-quality pharmaceutical research and service laboratory operations. • Government funding offers financial stability and long-term sustainability. • Strategic location within the UP system enables access to talented researchers, students, and industry connections. • Fosters collaboration and innovation, appealing to academic stakeholders and the pharmaceutical industry.
Weaknesses	• Limited industry experience may hinder the understanding of commercial client needs. • Challenges in establishing brand recognition and credibility as a new entity. • Need to address weaknesses for successful establishment and ongoing operation.
Opportunities	• Potential to establish industry partnerships to enhance analytical services. • Embracing technological advancements aligns with pharmaceutical industry interests. • Collaborations with local pharmaceutical manufacturers and traders to better understand industry demands.
Threats	• Competition from established companies offering similar analytical services could hinder market entry. • Stringent regulatory requirements may complicate compliance and adherence to industry standards. • Economic fluctuations and market uncertainties might affect demand for analytical services and overall revenue streams.

Conclusion

The UP PSSL holds immense potential to become a leading force in the pharmaceutical research and service laboratory landscape, driven by its academic expertise, strategic affiliations, and government funding. The urgency of the pandemic further underscores the need for advanced pharmaceutical research facilities like the UP PSSL to accelerate drug development, innovation, and healthcare solutions. By leveraging opportunities for industry partnerships, technological advancements, and collaborative innovation, the UP PSSL can align its interests with those of academic stakeholders and the pharmaceutical industry, contributing to improved patient outcomes, healthcare quality, and public health initiatives.

Acknowledgements

The researchers would like to express their sincere gratitude to the Department of Science and Technology-Science Education Institute for the fellowship opportunity provided as part of the scholarship privilege for Mr John Nicolas Mejia. We also wish to acknowledge the invaluable contributions of the Project 2 research staff (Dr. Francis Capule, Dr. Imelda Peña, Prof. Jocelyn Palacpac, Dr. Bryan Paul Bulatao, Prof. Edwin Ruamero and Prof. Maria Rosario Barangan) and research associates (Kenneth Ezeuba, Althea Gundran, Levent Bless Aquino and Janelle Lilith Fernandez-de Leon) to this study. Our appreciation extends to the stakeholders who participated in the Key Informant Interviews (KII) for sharing their valuable insights. Most especially, we are grateful to the Department of Science and Technology and the Philippine Council for Health Research and Development, the funding and monitoring agencies that supported the establishment of the UP PSSL. Thank you all for your continued collaboration and commitment in the service of the Filipino people.

References

1. Berk M, Otmar R, Dean O, Berk L, & Michalak E. (2015) The Use of Mixed Methods in Drug Discovery. In Elsevier eBooks (pp. 59–74). https://doi.org/10.1016/b978-0-12-405170-6.00006-3
2. Palanki R & Bose SK. (2023) Drug discovery and development. In Elsevier eBooks (pp. 35–41). https://doi.org/10.1016/b978-0-323-90300-4.00089-6
3. Crismundo K. (2015) PH pharma industry seen to hit P216-B in 2024. I Philippines News Agency. https://www.pna.gov.ph/articles/1172455
4. Murray AJ, Cox LR, Adcock HV, & Roberts RA. (2024) Academic drug discovery: Challenges and opportunities. Drug Discovery Today, 103918. https://doi.org/10.1016/j.drudis.2024.103918
5. Sams-Dodd F. (2007) Research & market strategy: how choice of drug discovery approach can affect market position. Drug Discovery Today, 12(7–8):314–318. https://doi.org/10.1016/j.drudis.2007.02.014
6. Yang W, Wang Y, Han D, Tang W, & Sun L. (2024) Recent advances in application of computer-aided drug design in anti-COVID-19 Virials Drug Discovery. Biomedicine & Pharmacotherapy, 173, 116423. https://doi.org/10.1016/j.biopha.2024.116423
7. Kumar S, Basu M, Ghosh P, Pal U, & Ghosh MK. (2023) COVID-19 therapeutics: Clinical application of repurposed drugs and futuristic strategies for target-based drug discovery. Genes & Diseases, 10(4):1402–1428. https://doi.org/10.1016/j.gendis.2022.12.019
8. Noh H, Yoon S, Kim S, *et al.* (2023) Establishment of multicenter COVID-19 therapeutics preclinical test system in Republic of Korea. Pulmonary Pharmacology & Therapeutics, 80, 102189. https://doi.org/10.1016/j.pupt.2023.102189
9. Cando LFT, Quebral EPB., Ong EP., *et al.* (2024) Current status of diabetes mellitus care and management in the Philippines. Diabetes & Metabolic Syndrome, 18(2), 102951. https://doi.org/10.1016/j.dsx.2024.102951
10. Kumari M, Bharti N, Kamiike A. (2021) Japan's investment in India: post covid-19 investment opportunities in pharmaceuticals. Transnational Corporations Review, 13(2):174–188. https://doi.org/10.1080/19186444.2021.1898860
11. Statistica. (2025) Pharmaceuticals. https://www.statista.com/outlook/hmo/pharmaceuticals/philippines
12. Onyinyi B & Asiimwe N. (2024) Key drivers of investment initiatives in Uganda's pharmaceutical industry. Social Science & Medicine, 344, 116558. https://doi.org/10.1016/j.socscimed.2024.116558
13. Ince B. (2024) How do regulatory costs affect mergers and acquisitions decisions and outcomes? Journal of Banking & Finance, 163, 107156. https://doi.org/10.1016/j.jbankfin.2024.107156
14. Ye Q, Huang R, & Tan KJK. (2023) Missing the boat: Regulatory approval delay and investment project outcomes. The British Accounting Review, 55(6), 101186. https://doi.org/10.1016/j.bar.2023.101186
15. Ingle RG, Zeng S, Jiang H, & Fang W. (2022) Current developments of bioanalytical sample preparation techniques in pharmaceuticals. Journal of Pharmaceutical Analysis/Journal of Pharmaceutical Analysis, 12(4), 517–529. https://doi.org/10.1016/j.jpha.2022.03.001
16. Elekidis AP, & Georgiadis MC. (2022) Optimal contract selection

for contract manufacturing organizations in the secondary pharmaceutical industry. Computers & Chemical Engineering, 165, 107957. https://doi.org/10.1016/j.compchemeng.2022.107957
17. Hassanzadeh F, Modarres M, Nemati HR, & Amoako-Gyampah K. (2014) A robust R&D project portfolio optimization model for pharmaceutical contract research organizations. International Journal of Production Economics, 158:18–27. https://doi.org/10.1016/j.ijpe.2014.07.001
18. Williams P, Cotta MO, Tabah A, *et al.* (2024) Antimicrobial Therapeutic Drug Monitoring in critically ill adult patients -an international perspective on access, utilisation, and barriers. International Journal of Antimicrobial Agents, 107192. https://doi.org/10.1016/j.ijantimicag.2024.107192
19. Maranchick NF, Peloquin CA. (2024) Role of therapeutic drug monitoring in the treatment of multi-drug resistant tuberculosis. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, 100444. https://doi.org/10.1016/j.jctube.2024.100444
20. The Taiwan News. (2024) Philippines Therapeutic Drug Monitoring (TDM) Market Emerging Players May Yields New Opportunities. https://www.taiwannews.com.tw/news/5075672
21. Fang Z, Zhang H, Guo J, & Guo J. (2024) Overview of therapeutic drug monitoring and clinical practice. Talanta, 266, 124996. https://doi.org/10.1016/j.talanta.2023.124996
22. Dhake PR, Kumbhar ST, & Gaikwad VL. (2024) Biowaiver based on biopharmaceutics classification system: Considerations and requirements. Pharmaceutical Science Advances, 2, 100020. https://doi.org/10.1016/j.pscia.2023.100020
23. Plano D, Rudolph N, Saal C, *et al*. (2024) Biowaiver Monograph for Immediate-Release Solid Oral dosage forms: isavuconazonium sulfate. Journal of Pharmaceutical Sciences, 113(2):386–395. https://doi.org/10.1016/j.xphs.2023.11.005
24. Mehta M, Polli J, Seo P, *et al.* (2023) Drug Permeability - Best Practices for Biopharmaceutics Classification System (BCS)-Based Biowaivers: A workshop Summary Report. Journal of Pharmaceutical Sciences, 112(7):1749–1762. https://doi.org/10.1016/j.xphs.2023.04.016
25. Department of Health. (2023)
26. Martir J, Flanagan T, Mann J, & Fotaki N. (2020) BCS-based biowaivers: Extension to paediatrics. European Journal of Pharmaceutical Sciences, 155:105549. https://doi.org/10.1016/j.ejps.2020.105549
27. Plöger GF, Quizon PM, Abrahamsson B, *et al.* (2020). Biowaiver monographs for immediate release solid oral dosage forms: Cephalexin monohydrate. Journal of Pharmaceutical Sciences, 109(6):1846–1862. https://doi.org/10.1016/j.xphs.2020.03.025